I agree, It is not great that this company is reactionary rather than being proactive. When the CD12 (and CD10) trials had approved protocols, I think everyone assumed we just needed to complete them and we are a covid drug company. Not many even thought what happens if we fail these trials. We can be optimistic, management should have a plan for the worst case scenario. We could have recruited more than the trial required, we could have had a more detailed DSMC review and we should have stood our ground on the 2 dose limit.